FLT3 and acute myeloid leukemia: In patients with newly diagnosed AML that was FLT3-ITD-positive, phase-1/2 trials revealed that quizartinib plus chemotherapy demonstrated anti-leukaemic effectiveness with a tolerable safety profile.